Given the elevated expression of IL-22R1 and S1PR1 in aggressive breast cancer, we analyzed the associations between the IL-22R1 and S1PR1 signatures and relapse free survival time in a cohort of 425 human breast cancer patients. This evidence concerns the gene IL22RA1 and breast carcinoma.